Quantcast Astrazeneca Submits US New Drug Application For Brilinta , An Investigational Antiplatelet - Congoo
 
 
Log In
AstraZeneca Submits US New Drug Application for Brilinta , an Investigational Antiplatelet
Have an interest in this Story?
Sign Up for Real-Time email updates
PharmaceuticalProcessing  | November 20, 2009

AstraZeneca today announced it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade n...
Read Full Article   
 
Leave a Comment: You must be logged in to leave a comment     Log in | Register
 

Featured Members
Niladri Roy Niladri Roy
Manager-International Marketing
Computer Services
Gordon Kauer Gordon Kauer
Sales Rep/News/On Air
Broadcasting Industry

  
  View more profiles

 
Access dozens of premium and subscriptions sites Free! Download now.

Advertise   |   Build a News Circle   |   Get News Briefings   |   Congoo News Home   |   Get the Netpass
About Congoo   |   Terms   |   Privacy   |   Need Help?   |   Site Map
Copyright ©2010 Congoo.com. All Rights Reserved.